The National Institute for Health Care Management says more than two fifths of the 18.8 percent increase in outpatient drug spending from 1999 to 2000 was attributable to higher demand. A bit more than a third of the spending increase was linked to newer medications.... HMOs begin declaring this month whether they will stay in Medicare. HealthMetrix Research predicts withdrawals displacing 700,000 members.... "Everyone in health care hates HCFA," Julie Rovner wrote in Congress Daily/AM the same week HHS Secretary Tommy Thompson decided to run the agency for one week. Thompson wanted to see how "we can do things better," but a new identity wasn't what others had in mind; at the end of the week, Thompson was considering changing HCFA's name to the Medicare and Medicaid Association.... One of the more interesting proposals floating around Washington comes from Kenneth Cooper, M.D., the president's reported choice to become the next surgeon general: tax deductions for meeting personal health targets, e.g., for cholesterol and blood pressure. Did someone say "Privacy"?.... Mary Jane England, M.D., is leaving the Washington Business Group on Health this month to become president of her alma mater, Regis College.... Beginning July 1, San Francisco city workers will be entitled to sex-change benefits for surgery, hormone therapy, and counseling.
House Republicans come out with their ACA alternative. A continuous coverage surcharge replaces the individual mandate. But where’s the CBO score?
The biosimilar segment of the pharmaceutical industry is on fire. Some 700 biosimilars are at some stage of development, and more than 660 companies are involved in some way in the biosimilars land rush. Still, only a handful may get on the market in the next few years.
No one knows how much of an effect biosimilars will have on oncology expenditures. Pricing and market share are in a large, opaque “to be determined” cloud. But there’s certainly potential for a major impact that could lower oncology expenditures by millions, if not billions.
The future of biosimilars in this country is nothing if not uncertain. Most immediately, the U.S. Supreme Court is hearing a case that will determine the timing of the 180-day waiting period before a biosimilar can go on the market. But there are larger and longer-term issues at play as well.
While coupons help individual consumers, they are also having a major impact on the insurance industry and anyone responsible for paying health care bills. Insurers and pharmacy benefit managers complain that they foil formularies and other pricing strategies designed to steer consumers to less-expensive drugs.
The hard truth is that telehealth’s future—its size, its contours—will depend a lot on what payers will be willing to pay for. Currently, commercial plans cover only a limited number of services. In addition, research suggests that there may be quality and utilization problems.
Insurers should consider covering new drug-delivery devices that can improve outcomes while lowering disease-specific pharmacy and long-term overall health care costs. Managing these devices in the pharmacy benefit will consolidate volume-based purchasing and capitalize on PBM strategies for improving adherence.
Basaglar is coming on the scene during tumultuous times for insulin products. Manufacturers are under attack for price hikes. There are allegations of backroom rebate deals. And a class-action lawsuit has been brought on behalf of uninsured patients, charging insulin makers with setting artificially high prices.
Evaluating the quality of telemedicine care is about as easy as evaluating the quality of health care, period, and researchers are still ironing out the methodological kinks. That may be one reason research results are all over the place. This article involved reviewing nine such studies, and the findings are a mixed bag.
If millions of Americans lose Medicaid or private health insurance coverage because of the unACAing of American health care, telehealth may seem like a gimmicky sideshow rather than a good-faith effort to bring health care into the digital century.